CN103535574B - Royal jelly composition and preparation method thereof - Google Patents
Royal jelly composition and preparation method thereof Download PDFInfo
- Publication number
- CN103535574B CN103535574B CN201210243301.8A CN201210243301A CN103535574B CN 103535574 B CN103535574 B CN 103535574B CN 201210243301 A CN201210243301 A CN 201210243301A CN 103535574 B CN103535574 B CN 103535574B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- royal jelly
- vitamin
- composition
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940109850 royal jelly Drugs 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 66
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 45
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 45
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 45
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 33
- 239000011718 vitamin C Substances 0.000 claims abstract description 33
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 47
- 239000002994 raw material Substances 0.000 claims description 24
- -1 VE-succinate Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 5
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 abstract 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 abstract 2
- 239000008176 lyophilized powder Substances 0.000 abstract 2
- 238000005453 pelletization Methods 0.000 abstract 1
- 239000007779 soft material Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 230000009182 swimming Effects 0.000 description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 22
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229940096919 glycogen Drugs 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 229930003427 Vitamin E Natural products 0.000 description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 11
- 239000011709 vitamin E Substances 0.000 description 11
- 235000019165 vitamin E Nutrition 0.000 description 11
- 229940046009 vitamin E Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100026189 Beta-galactosidase Human genes 0.000 description 9
- 108010059881 Lactase Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 229940116108 lactase Drugs 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 235000009754 Vitis X bourquina Nutrition 0.000 description 7
- 235000012333 Vitis X labruscana Nutrition 0.000 description 7
- 240000006365 Vitis vinifera Species 0.000 description 7
- 235000014787 Vitis vinifera Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010067162 Asthenospermia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- LRYFTDGIIUTFFA-UHFFFAOYSA-N Tocopheronic acid Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)CCC(O)=O)=C(C)C1=O LRYFTDGIIUTFFA-UHFFFAOYSA-N 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- YUKCLPPRYNXRAF-UHFFFAOYSA-N (+-)-16-Epiormosanin Natural products N1CCCCC1C1(CN2CCCCC22)C3NCCCC3CC2C1 YUKCLPPRYNXRAF-UHFFFAOYSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241001661920 Telosma Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011987 exercise tolerance test Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108010003814 member 2 group B nuclear receptor subfamily 0 Proteins 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a royal jelly composition and a preparation method thereof. The composition is prepared from royal jelly lyophilized powder, L-carnitine, grape seed extract, vitamin C and vitamin E succinate. The preparation method comprises the following steps: mixing L-carnitine, grape seed extract and vitamin E succinate; adding ethanol, and mixing to prepare a soft material; pelletizing, drying and granulating; adding royal jelly lyophilized powder and vitamin C, uniformly mixing, and tabletting. The invention also provides application of the royal jelly composition in preparation of medicaments for relieving physical fatigue.
Description
Technical field
The present invention relates to a kind of composition and method of making the same, particularly the preparation method of a kind of royal jelly composition and tablet thereof.
Background technology
The energy " exhaustion " theory for tired mechanism: energy is mainly derived from sugar, fat, protein and aerobic or anaerobic metabolism, and along with the prolongation of run duration, energy substance is exhausted, body can not maintain predetermined strength, has occurred fatigue.
Royal jelly is a kind of milky or flaxen corpus mamillare of being secreted by adult worker bee Shang hypopharyngeal gland, outside three large nutritions, also containing vitamin, several mineral materials, various bioactivators; The main function of l-cn is transported in film by LCFA with the form of fat phthalein carnitine from mitochondrial membrane as carrier, carries out beta oxidation, produce power in mitochondria; L-cn can regulate acyl group ratio in mitochondria, can also can participate in the transport of branched-chain amino acid metabolite, ensure normal energetic supersession; L-cn can discharge excessive in body or irrational acyl group group, eliminates the metabolism toxicity that body causes because of acyl group accumulation, can also promote the oxidation of second phthalein acetic acid, work in the elimination and utilization of ketoboidies, prevent the toxicity that in animal body, excess ammonia produces; L-cn can be used as biological anti-oxidant scavenging free radicals, maintains the stable of film, improves the immunity of animal and the ability of disease-resistant resisting stress; Grape seed extract contains OPC, Tea Polyphenols and natural VE three kinds of compositions, is a kind of free radical scavenger, high-performance bio antioxidant; Vitamin C is polyphenoils heavy in chemical reaction inside and outside human body cell, play an important role in cellular oxidation defence, participate in and promote that between collagen and tissue, cementin is formed, the co-factor of multiple enzyme or auxiliary substrate, body can be strengthened to infectious disease resistivity, improve adaptive capacity, all have important regulative to humoral immunity, cellular immunity; Vitamin E, also known as " tocopherol ", belongs to liposoluble vitamin.Vitamin E can suppress the generation of free radical, and Human Umbilical Vein Endothelial Cells has important protective effect, can maintain the stable of endothelial cell endocrine function.
In the prior art, application number is in the Chinese invention patent of CN201010168399.6, disclose 29 kinds of raw materials such as adopting grape juice, grape pip juice, SOD, glutathione, nucleotides, royal jelly manufacture SOD grape health care wine technology through front and back fermenting twice, make this product can play the effect strengthening body immunity and resistance; Be in the Chinese invention patent of CN200410009332.2 at application number, disclose a kind of food with health role containing pollen, royal jelly, grape seed extract, this product has the multi-efficiencies such as auxiliary beauty treatment, delaying senility, raising immunity; Be in the Chinese invention patent of CN200510019602.2 at application number, disclose a kind of health honey concentrated juice, its formulation weight percentage is honey, rice vinegar, grape juice, royal jelly dried powder, the functions such as this product has liver-protecting and alcoholism-relieving, skin maintenance, anti-ageing, defaecation is secret, softening blood vessel; Be in the Chinese invention patent of CN200510123935.X at application number, disclose a kind of health products with radiation-resisting functional and preparation method thereof, the composition that it is is component with extracts such as gadol extract, grape seed extract, royal jelly freeze-dried powder, propolis; Be in the Chinese invention patent of CN200910081850.8 at application number, disclose a kind of nutraceutical with anti-oxidation function and preparation method thereof, make primarily of following medicine and food raw materials: stone column ginseng, chrysanthemum, Sessileflower Acanthopanax Bark tea, Poria cocos, Semen sesami nigrum, peach kernel, Bee Pollen, white fungus, black fungus, Hericium erinaceus, mushroom, grape pip, lycopene, royal jelly, this product has obvious oxidation resistant effect, can also improve immunity simultaneously; Be in the Chinese invention patent of CN02157385.9 at application number, disclose a kind of adjusting blood lipid composition, said composition is made up of royal jelly freeze-dried powder, rape pollen, propolis, vitamin C, maltodextrin; Be in the Chinese invention patent of CN200910117322.3 at application number, disclose a kind of for improving or control mankind subhealth symptom, anti-ageing oral agents, adopt honey, royal jelly, inosine, vitaminAD, vitamin C, B1, B2, licorzinc combination formula, anti-ageing for improving inferior health; Be in the Chinese invention patent of CN200510036965.7 at application number, disclose a kind of snail health products, be made up of following raw material: snail freeze-dried powder, royal jelly freeze-dried powder, vitamin C, dietary fiber are, galactolipin; Be in the Chinese invention patent of CN200510114726.9 at application number, disclose a kind of nutrient preventing to die suddenly, with the linoleic acid of pure natural, leukotrienes for matrix, take tocopheronic acid as powerful antioxidant, with the best of breed of general and trace elements potassium, calcium, magnesium, zinc, selenium and the nutrient such as vitamin V A, VC, VE and royal jelly, honey, algal polysaccharides, collagen, make the nutrient of a kind of nutrition " cardiac muscle ", " heart and brain " cell, prevention sudden death; Be in the Chinese invention patent of CN200810224200.X at application number, disclose a kind of for preventing the pharmaceutical composition of inborn defect and Improving memory, comprise the bighead atractylodes rhizome, royal jelly, vitamin A, beta carotene, vitamin B compound, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium, mainly be applicable to pregnant front women, pregnant woman, wet nurse, very effective in prevention inborn defect and Improving memory; Be in the Chinese invention patent of CN200910039183.7 at application number, disclose a kind of health food with enhancing body immunity and supplementary mineral matter function, comprise following component: FOS, taurine, aloe extract, royal jelly, pollen, vitamin C, lysine, alanine, mineral mixture; Be in the Chinese invention patent of CN200610163286.0 at application number, disclose a kind of health food with fat-reducing and anti-oxidation function, be made up of grape seed extract, oolong tea extract, l-cn, wheat-germ oil; Be in the Chinese invention patent of CN200910061078.3 at application number, disclose one and can be applicable to women's body shaping, gynaecologic antibiotic anti-inflammatory, improve the preparation of Female sexual quality of life, be made up of l-cn, collagen, amino acid, grape pip, chamomile, Sodium Benzoate, Nano silver solution, water miscible Laurocapram, carbomer, propane diols, cordate telosma essence etc.In paper " combined L-carnitine and acetyl-L-carnitine compound formulation and vitamin E use in conjunction are on the impact of idiopathic asthenospermia sperm quality ", describe combined L-carnitine and acetyl-L-carnitine compound formulation and vitamin E use in conjunction to the impact of idiopathic asthenospermia sperm quality; In paper " vitamin E and l-cn improve the clinical observation of Maintenance Hemodialysis Patients renal anemia ", describe vitamin E and the effect of l-cn (VBT) in uremic renal anemia treatment; At paper " Effects of L-carnitine, royal jelly and pomegranateseed on peripheral blood cells in rats ", " Support therapy with integrators aftervaricocelectomy ", in " Ergogenic aids:Sports performance effect of a nutritionalcomplex ", describe the correlative study that royal jelly and l-cn combine; at paper " Chronicdietary supplementation of proanthocyanidins corrects the mitochondrialdysfunction of brown adipose tissue caused by diet-induced obesity in Wistarrats ", " Proanthocyanidins modulate triglyceride secretion by repressing theexpression of long chain acyl-CoA synthetases in Caco2 intestinal cells ", " Agrape polyphenol extract modulates muscle membrane fatty acid composition andlipid metabolism in high-fathigh-sucrose diet-fed rats ", " Use of complementaryand alternative medicine among adults with skin disease ", " Nutrientsupplementation approaches in the treatment of ADHD ", " Effect of lycopene oncyclophosphamide-induced hemorrhagic cystitis in rats ", " Dietary procyanidinslower triglyceride levels signaling through the nuclear receptor small heterodimerpartner ", " Effect of grape seed water extract on lipid metabolism and erythrocyteantioxidant defense system in high-fat diet-induced obese C57BL/6 mice ", " Natural compounds:Evidence for a protective role in eye disease ", " Patternsof usage of complementary and alternative medicine in general surgicalpatients ", in " Nutritional issues and supplements in amyotrophic lateral sclerosisand other neurodegenerative disorders ", describe the correlative study that l-cn and grape pip combine.
At present, in the prior art, relating to royal jelly, l-cn, grape pip or vitamin, to have the document of health care a lot, but the report relating to the mutual combination of this several raw material is less, and there is no above-mentioned raw materials optimum organization is played synergistic research and report.
Summary of the invention
The object of the invention is to provide a kind of royal jelly composition, and another object of the present invention is the Preparation method and use providing said composition.
The present invention seeks to be achieved through the following technical solutions
The raw material of royal jelly composition of the present invention consists of:
Royal jelly freeze-dried powder 60-100 weight portion, l-cn 60-100 weight portion, grape seed extract 30-80 weight portion, vitamin C 10-40 weight portion, VE-succinate 5-30 weight portion.
Above-mentioned raw materials preferred weight proportioning is as follows:
Royal jelly freeze-dried powder 83.3 weight portion, l-cn 83.3 weight portion, grape seed extract 50 weight portion, Catergen 5 weight portion, VE-succinate 16.7 weight portion.
Above-mentioned raw materials preferred weight proportioning is as follows:
Royal jelly freeze-dried powder 72 weight portion, l-cn 90 weight portion, grape seed extract 43 weight portion, Catergen 9 weight portion, VE-succinate 12 weight portion.
Above-mentioned raw materials preferred weight proportioning is as follows:
Royal jelly freeze-dried powder 91 weight portion, l-cn 72 weight portion, grape seed extract 57 weight portion, Catergen 1 weight portion, VE-succinate 20 weight portion.
Above-mentioned raw materials adds customary adjuvant, and conveniently technique makes the formulation that acceptable capsule, tablet, pill, granule, powder, liquid preparation or other any one pharmacies are mentioned.
The concrete preparation method of royal jelly composition tablet of the present invention is as follows:
Get raw material l-cn, grape seed extract, VE-succinate, mix with the microcrystalline cellulose of 80-90 weight portion, add 80% ethanol, cross 20 eye mesh screens and granulate; Fluidized drying 40-60 minute, after naturally cooling to room temperature, crosses the whole grain of 20 mesh sieve; Add royal jelly freeze-dried powder, vitamin C, mix, compressing tablet, make tablet.
Royal jelly composition of the present invention can significantly relieve chronic be tired, strengthens body tolerance, obviously slows down the damage of free radical and the generation of fatigue, alleviating physical fatigue.
Following experimental example and embodiment are used for further illustrating but are not limited to the present invention.
Experimental example 1 exercise tolerance is tested
1. experiment purpose
By exercise tolerance test (mouse forced swimming), observe the antifatigue effect of royal jelly composition of the present invention, for determining that formula consumption provides experimental basis.
2. experiment material and reagent
2.1 for reagent thing
Prescription one (G1): royal jelly freeze-dried powder 83.3g;
Prescription two (G2): l-cn 83.3g;
Prescription three (G3): grape seed extract 50g;
Prescription four (G4): vitamin C 25g;
Prescription five (G5): VE-succinate 16.7g;
Prescription six (G6): royal jelly freeze-dried powder 83.3g, l-cn 83.3g;
Prescription seven (G7): royal jelly freeze-dried powder 83.3g, grape seed extract 50g;
Prescription eight (G8): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, grape seed extract 50g;
Prescription nine (G9): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, VE-succinate 16.7g
Prescription ten (G10): l-cn 83.3g, grape seed extract 50g;
Prescription 11 (G11): l-cn 83.3g, vitamin C 25g;
Prescription 12 (G12): l-cn 83.3g, grape seed extract 50g, vitamin C 25g;
Prescription 13 (G13): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, grape seed extract 50g, vitamin C 25g;
Prescription 14 (G14): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, grape seed extract 50g, VE-succinate 16.7g;
Prescription 15 (G15): l-cn 83.3g, grape seed extract 50g, vitamin C 25g, VE-succinate 16.7g;
Prescription 13 (G13): royal jelly freeze-dried powder 83.3g, grape seed extract 50g, Catergen 5g, VE-succinate 16.7g;
Prescription 14 (G14): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, vitamin C 25g, VE-succinate 16.7g;
Prescription 15 (G15): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, grape seed extract 50g, vitamin C 25g;
Prescription 16 (G16): royal jelly freeze-dried powder 83.3g, l-cn 83.3g, grape seed extract 50g, vitamin C 25g, VE-succinate 16.7g;
Prescription 17 (G17): royal jelly freeze-dried powder 72g, l-cn 90g, grape seed extract 43g, Catergen 9g, VE-succinate 12g;
Prescription 18 (G18): royal jelly freeze-dried powder 91g, l-cn 72g, grape seed extract 57g, Catergen 1g, VE-succinate 20g;
Prescription 19 (G19): royal jelly freeze-dried powder 60g, l-cn 100g, grape seed extract 30g, vitamin C 40g, VE-succinate 30g.
Prescription 20 (G20): royal jelly freeze-dried powder 100g, l-cn 60g, grape seed extract 80g, vitamin C 10g, VE-succinate 5g.
2.2 reagent:
Liver/muscle glycogen testing cassete, builds up institute of biological products purchased from Nanjing;
The concentrated sulfuric acid (AR), Nanjing Chemistry Reagent Co., Ltd.;
Physiological saline, Shangdong Changfu Jiejing Pharmaceutical Industry Co., Ltd..
3. animal used as test
ICR mouse, ♂, cleaning grade, body weight 18-22g, is provided by Yangzhou University's comparative medicine center,
The quality certification number: SCXK(revives) 2007 – 0001, the free diet of experimental session mouse.
4. key instrument
Aluminum swimming trunk (50cm × 50cm × 40cm), galvanized wire, low-temperature and high-speed centrifuge: 5804R type, Eppendrof company; Water-bath: DK-S26 type, the grand experimental facilities Co., Ltd of upper Nereid; Electronic scale: BS224S type, Sartorius company; Stopwatch, thermometer
5. experiment grouping
5.1 dosage groupings and given the test agent give the time
At random mouse is divided into 21 groups, often organizes 10, give the medicine of G1 ~ G20 respectively for the 1st group to the 20th group, the 21st group is blank group, gives isopyknic distilled water, often the every average daily gavage of group 1 time, and gavage volume is 0.2ml/10g, gives given the test agent continuously 30 days.
5.2 sample preparation
1st group to the 20th group: take 2.25g drug sample, be assigned to 150ml with distilled water;
Blank group: distilled water 150ml.
6. experimental technique
6.1 after swimming with a load attached to the body experiment last administration 30min, put mouse in swimming trunk, the depth of water is no less than 30cm, water temperature 25 ± 1 DEG C, the sheet lead of mouse root of the tail portion load 5% body weight, and the swimming of record mouse starts to the dead time, as mouse swimming time.
After 6.2 mice serum urea measure last administration 30min, be not swimming with a load attached to the body 90min in the water of 30 DEG C in temperature, eyeball blood sampling 0.5mL (not adding anti-coagulants) is plucked after rest 60min, put 4 DEG C of refrigerator 3h, the centrifugal 15min of 2000r/min after blood clotting, gets serum and send clinical laboratory of Lianyungang First People's Hospital to detect.
After the mensuration last administration 30min of 6.3 hepatic glycogen, be not swimming with a load attached to the body 90min in the water of 25 ± 1 DEG C in temperature, cervical dislocation puts to death mouse, clean with physiological saline, and with after filter paper suck dry moisture, accurately taking liver 100mg, hepatic glycogen detection kit detects Mouse Liver glycogen content.
Take a blood sample after the mensuration last administration 30min of 6.4 blood lactase acid, then do not bear a heavy burden stops after temperature is the water went swimming 10min of 30 DEG C.Lactic acid instrument assay method: after rest 20min, each blood sampling 20 μ L add in 40 μ L rupture of membranes liquid before swimming, after swimming, after swimming respectively, the smudge cells lactic acid instrument that fully vibrates immediately measures.(blood lactase acid TG-AUC=5 × (the blood lactase acid value of the rear 20min of blood lactase acid value+2 × swimming of the rear 0min of front blood lactase acid value+3 × swimming that swims)
7. observation index walking weight load, blood lactase acid, urea, glycogen initial value
8. statistical method experimental data is used
represent, employing t inspection is compared between organizing
9. experimental result
9.1 present compositions are on the impact of Mouse Weight
Each group of mouse is after giving G1 ~ G20 medicine, before, in, shown in post-weight sees the following form respectively, the original body mass of each group mouse and increase weight body weight and the more equal no difference of science of statistics of control group (P > 0.05), show G1 ~ G20 medicine all without obvious toxicity.Experimental result refers to table 1.
The original body mass of table 1 swimming with a load attached to the body experiment mice, mid-term body weight and terminate body weight
9.2 present compositions are on the impact of mice burden swimming time
After per os gives mouse G1 ~ G20 medicine, G1 ~ G15 medicine compares with blank group, can obviously extend the mice burden swimming time, there is significant difference (P < 0.05), present composition G16 ~ G20 medicine compares with blank group, can the significant prolongation mice burden swimming time, there is pole significant difference (P < 0.01), and be obviously better than G1 ~ G15 medicine.The results detailed in Table 2.
Table 2 royal jelly composition of the present invention is on the impact of mice burden swimming time
" * " p<0.05vs blank; " * * " p<0.01vs blank;
9.3 present compositions are on the impact of blood lactase acid before and after mouse movement
After per os gives mouse royal jelly composition of the present invention, present composition G16 ~ G20 medicine to compare with control group blood lactase acid TG-AUC after mouse movement significant difference (P < 0.05), decrease though G1 ~ G15 medicine group Mouse Blood lactic acid TG-AUC compares with control group, and no difference of science of statistics (P > 0.05).The results are shown in Table 3.
Table 3 royal jelly composition of the present invention is on the impact of blood lactase acid level before and after mouse movement
" * " p<0.05vs blank;
9.4 present compositions are on the impact of Mouse Liver glycogen
After per os gives mouse G1 ~ G20 medicine, G1 ~ G15 medicine compares with blank group, Mouse Liver glycogen content all has obvious rising, there is significant difference (P < 0.05), present composition G16 ~ G20 medicine compares with blank group, Mouse Liver glycogen content all has obvious rising, has pole significant difference (P < 0.01), and is obviously better than G1 ~ G15 medicine.The results detailed in Table 4.Table 4 royal jelly composition of the present invention is on the impact of Mouse Liver glycogen content
" * " p<0.05vs blank; " * * " p<0.01vs blank;
9.5 present compositions are on the impact of mice serum urea
After per os gives mouse G1 ~ G20 medicine, G1 ~ G15 medicine group compares with blank group, after mouse movement, serum urea content all has obvious reduction, there is significant difference (P < 0.05), present composition G16 ~ G20 medicine compares with blank group, after mouse movement, serum urea content all has obvious reduction all to have obvious reduction, has pole significant difference (P < 0.01), and is obviously better than G1 ~ G15 medicine.The results detailed in Table 5.
Table 5 royal jelly composition of the present invention is on the impact of mice serum urea content
" * " p<0.05vs blank; " * * " p<0.01vs blank;
10. experiment conclusion
This experiment is mainly through mice burden swimming experiment, and the deposit simultaneously detecting Mouse Liver glycogen observes the antifatigue effect of royal jelly composition of the present invention.Preliminary Results shows below:
1, G16 ~ G20 composition of the present invention all can extend the mice burden swimming time (P < 0.01), and successful is better than the composition of other G1 ~ G15.
2, biochemistry detection aspect display, the lactic acid content that after each dosage group of G16 ~ G20 composition of the present invention all can reduce motion, in mice serum, glucose anerobic glycolysis produces, compare with control group and have significant difference (P < 0.05), and although the composition of other G1 ~ G15 also can reduce the lactic acid content that in the rear mice serum of motion, glucose anerobic glycolysis produces, but compare with control group, no difference of science of statistics (P > 0.05);
3, each dosage group of G16 ~ G20 composition of the present invention all can significantly improve the deposit (P < 0.01) of glycogen in mouse liver, and successful is better than the composition of other G1 ~ G15;
4, high lithemia model finds, G16 ~ G20 composition of the present invention significantly can reduce the content (P < 0.01) of the rear urea in serum of mouse swimming, and successful is better than the composition of other G1 ~ G15;
11. discuss
Above-mentioned experiment proves that the present composition significantly can reduce the content of urea in serum and lactic acid after mouse movement, and the deposit of glycogen in mouse liver can be significantly improved, point out it can reduce the loss of energy by the metabolism of two large main energetic matter protein and glucose in minimizing energetic supersession, contribute to the fatigue that alleviation exercise load causes; The time that mice burden swimming to power exhausts can be extended.
Present composition primary raw material is royal jelly freeze-dried powder, for tired generation mechanism, also added l-cn, grape seed extract, vitamin C, vitamin E, has the health care of alleviating physical fatigue.Add l-cn and play facilitation in Power supply step, alleviation organism fatigue is played to effectively acting on.Adding grape seed extract can alleviating physical fatigue effectively; grape pip procyanidin can be protected and stable vitamin C; and contribute to ascorbic absorption; reduction vitamin E free radical and vitamin E is regenerated thus reduces the loss of intracellular Vitamin E; strengthen and maintain the normal antioxidant level of body, slow tired generation.Obviously can slow down the damage of free radical and the generation of fatigue, help alleviating physical fatigue.
Following embodiment all can realize the effect described in above-mentioned experimental example.
The preparation of embodiment 1 royal jelly composition tablet
Royal jelly freeze-dried powder 83.3g l-cn 83.3g grape seed extract 50g
Catergen 5g VE-succinate 16.7g
Make 1000, tablet (the heavy 0.35g of every sheet)
Get above-mentioned l-cn, grape seed extract, VE-succinate, mix with the microcrystalline cellulose of 85g, add 80% ethanol, cross 20 eye mesh screens and granulate; Fluidized drying 40-60 minute, after naturally cooling to room temperature, crosses the whole grain of 20 mesh sieve; Add royal jelly freeze-dried powder, vitamin C, mix, compressing tablet, make tablet.
The preparation of embodiment 2 royal jelly composition tablet
Royal jelly freeze-dried powder 72g, l-cn 90g, grape seed extract 43g, Catergen 9g, VE-succinate 12g.
Get above-mentioned royal jelly freeze-dried powder, l-cn, grape seed extract, VE-succinate, vitamin C, mixing, add silica, dextrin, starch, phosphate, carbonate, sweet mellow wine, sorbierite, sorbic acid or sylvite, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol etc. dilution auxiliary material in one or more, dry, pulverize, sieve, compressing tablet, makes tablet.
The preparation of embodiment 3 royal jelly composition tablet
Royal jelly freeze-dried powder 91g, l-cn 72g, grape seed extract 57g, Catergen 1g, VE-succinate 20g.
Get above-mentioned l-cn, grape seed extract, VE-succinate, mix with the microcrystalline cellulose of 81g, add suitable 75% ethanol, mixing, makes softwood, granulates, and dry, whole grain, adds royal jelly freeze-dried powder, vitamin C, mix, compressing tablet.
The preparation of embodiment 4 royal jelly composition hard shell capsules
Royal jelly freeze-dried powder 83.3g l-cn 83.3g grape seed extract 50g Catergen 5g
VE-succinate 16.7g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique is encapsulated, to obtain final product.
The preparation of embodiment 5 royal jelly composition pill
Royal jelly freeze-dried powder 72g, l-cn 90g, grape seed extract 43g, Catergen 9g, VE-succinate 12g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique pill, to obtain final product.
The preparation of embodiment 6 royal jelly composition oral liquid
Royal jelly freeze-dried powder 91g, l-cn 72g, grape seed extract 57g, Catergen 1g, VE-succinate 20g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique, make oral liquid.
The preparation of embodiment 7 royal jelly composition soft
Royal jelly freeze-dried powder 85g, l-cn 65g, grape seed extract 70g, vitamin C 30g, VE-succinate 28g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique, make soft capsule.
The preparation of embodiment 8 royal jelly composition powder
Royal jelly freeze-dried powder 60g, l-cn 100g, grape seed extract 30g, vitamin C 40g, VE-succinate 30g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique, make powder.
The preparation of embodiment 9 royal jelly composition grain
Royal jelly freeze-dried powder 100g, l-cn 60g, grape seed extract 80g, vitamin C 10g, VE-succinate 5g.
Get above-mentioned raw materials, add customary adjuvant, conveniently technique, make particle.
Claims (7)
1. a royal jelly composition, is characterized in that the raw material of said composition consists of:
Royal jelly freeze-dried powder 60-100 weight portion, l-cn 60-100 weight portion, grape seed extract 30-80 weight portion, vitamin C 10-40 weight portion, VE-succinate 5-30 weight portion.
2. royal jelly composition as claimed in claim 1, is characterized in that the raw material of said composition consists of:
Royal jelly freeze-dried powder 83.3 weight portion, l-cn 83.3 weight portion, grape seed extract 50 weight portion, vitamin C 25 weight portion, VE-succinate 16.7 weight portion.
3. royal jelly composition as claimed in claim 1, is characterized in that the raw material of said composition consists of:
Royal jelly freeze-dried powder 72 weight portion, l-cn 90 weight portion, grape seed extract 43 weight portion, vitamin C 29 weight portion, VE-succinate 12 weight portion.
4. royal jelly composition as claimed in claim 1, is characterized in that the raw material of said composition consists of:
Royal jelly freeze-dried powder 91 weight portion, l-cn 72 weight portion, grape seed extract 57 weight portion, vitamin C 21 weight portion, VE-succinate 20 weight portion.
5. the preparation method of the royal jelly composition as described in claim 1,2,3 or 4, is characterized in that the method comprises the following steps:
Get raw material and add customary adjuvant, conveniently technique makes the formulation that acceptable capsule, tablet, pill, granule, powder, liquid preparation or other any one pharmacies are mentioned.
6. the preparation method of the tablet of the royal jelly composition as described in claim 1,2,3 or 4, is characterized in that the method comprises the following steps:
Get raw material l-cn, grape seed extract, VE-succinate, mix with the microcrystalline cellulose of 80-90 weight portion, add 80% ethanol, cross 20 eye mesh screens and granulate; Fluidized drying 40-60 minute, after naturally cooling to room temperature, crosses the whole grain of 20 mesh sieve; Add royal jelly freeze-dried powder, vitamin C, mix, compressing tablet, make tablet.
7. the royal jelly composition as described in claim 1,2,3 or 4 is preparing relieve chronic fatigue, strengthens the application in the medicine of body tolerance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210243301.8A CN103535574B (en) | 2012-07-13 | 2012-07-13 | Royal jelly composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210243301.8A CN103535574B (en) | 2012-07-13 | 2012-07-13 | Royal jelly composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103535574A CN103535574A (en) | 2014-01-29 |
| CN103535574B true CN103535574B (en) | 2015-03-25 |
Family
ID=49959737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210243301.8A Active CN103535574B (en) | 2012-07-13 | 2012-07-13 | Royal jelly composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103535574B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1270624C (en) * | 2004-07-14 | 2006-08-23 | 北京东方兴企食品工业技术有限公司 | Pollen, bee milk food and its preparation method |
| CN100420391C (en) * | 2006-12-18 | 2008-09-24 | 东北虎药业股份有限公司 | Health-care food with anti-oxidation and lowering weight functions |
| CN101518336A (en) * | 2009-04-14 | 2009-09-02 | 北京惠中铭捷生物科技有限公司 | Nutrition food with oxidation resistance function and preparation method thereof |
| CN101810336B (en) * | 2010-04-30 | 2012-03-21 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
-
2012
- 2012-07-13 CN CN201210243301.8A patent/CN103535574B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103535574A (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| CN110338412A (en) | The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application | |
| CN103918966A (en) | Composition containing Haematococcus pluvialis | |
| CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN105079309B (en) | Composition for relaxing bowel | |
| CN108703364A (en) | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof | |
| CN104397538A (en) | Health-care diet food | |
| CN110192583A (en) | With the composition and application for promoting intestinal health, control weight and raising to be immunized | |
| CN103750094B (en) | Male hachinoko health-care paste and preparation method thereof | |
| CN102090637A (en) | Collagen-containing compound nutritious powder | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN111357891A (en) | Plant beverage containing artichoke and ginseng and preparation method thereof | |
| CN106912920A (en) | A kind of composition containing mulberry-leaf extract and application thereof | |
| CN106912940A (en) | A kind of composition containing L-arabinose and application thereof | |
| CN103535574B (en) | Royal jelly composition and preparation method thereof | |
| CN108208813A (en) | A kind of weight-reducing with health role disappears fat piece and preparation method thereof | |
| WO2014134830A1 (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN109157548B (en) | Composition with functions of resisting fatigue and tonifying yang and preparation method thereof | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN102266051B (en) | Antifatigue composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |